Paul Tappenden BA (Nottingham Trent), MSc (Sheffield), PhD (Sheffield)

Professor of Health Economic ModellingTappenden1

University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA

Office: 2013

Tel: (+44) (0)114 222 0855
Fax: (+44) (0)114 222 0749


ORCiD: 0000-0001-6612-2332


I have over 17 years’ experience in designing, developing and critically appraising health economic models across a wide range of disease areas. Since joining ScHARR in 2000, I have been involved in the assessment of numerous health technologies for the National Institute for Health and Care Excellence (NICE), including beta-interferon and glatiramer-acetate for multiple sclerosis, anti-TNFs for ulcerative colitis, inhaled therapies for cystic fibrosis and TKIs for medullary thyroid cancer. I have also undertaken modelling assessments for the National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre (NETSCC), the Advisory Group for National Specialised Services (AGNSS), the Department of Health and NHS Cancer Screening Programmes, including an options appraisal of colorectal cancer screening programmes. In 2011, I completed an NIHR-funded fellowship evaluating the role and value of health economic models of whole disease and treatment pathways (Whole Disease Modelling).

Professional activities

I am the Director of Modelling for the ScHARR Technology Assessment Group and a member of the NICE Decision Support Unit (DSU). I am a member of NICE Technology Appraisal Committee C.

Research interests

My main research interests are:

• Health economic modelling
• Conceptual modelling
• Whole disease modelling

Teaching interests

• I am module lead for HAR691 (Using evidence in the design and development of models)
• I am an active PhD supervisor (3 current PhD students)

Current projects

Amongst others, I am currently working on the following projects:

• Technology assessments to inform the NICE Technology Appraisal Programme (various)
• Economic analysis of interventions to improve adherence to nebulised therapies in patients with cystic fibrosis (alongside the CF ACtiF trial)
• Modelling the potential cost-effectiveness of interventions for amyotrophic lateral sclerosis (part of the ALS-CARE study)

Extended List of Publications

Journal articles